1. Scrip
  2. >>R&D
  3. >>Clinical Trials

J&J’s Rybrevant/Lazcluze MARIPOSA Update Shows Greater Gains Over Tagrisso

Subcutaneous Rybrevant Data Reinforce Safety, Convenience

 
• By Mandy Jackson

Survival and other benefits with J&J’s EGFR/MET inhibitor Rybrevant plus EGFR inhibitor Lazcluze relative to AstraZeneca’s Tagrisso in first-line EGFR-mutant NSCLC continued to improve at 31.1 months.

3d rendered, medically accurate illustration of lung cancer. showing presence of cancerous tumor inside the lungs
Rybrevant plus Lazcluze efficacy continued to separate from Tagrisso monotherapy • Source: Shutterstock

Johnson & Johnson has evidence that the benefits of dual treatment with the firm’s EGFR/MET inhibitor Rybrevant (amivantamab) and EGFR inhibitor Lazcluze (lazertinib) improve over time from updated results from the Phase III MARIPOSA clinical trial of the two-drug combination versus AstraZeneca PLC’s standard-of-care EGFR inhibitor Tagrisso (osimertinib) in first-line non-small cell lung cancer (NSCLC) with EGFR mutations.

Key Takeaways

  • Updated results from the Phase III MARIPOSA study of Johnson & Johnson’s newly approved Rybrevant/Lazcluze combination regimen for first-line treatment of EGFR-mutant NSCLC showed that benefits relative to Tagrisso monotherapy continued to improve over time.

The US Food and Drug Administration approved Rybrevant plus Lazcluze for first-line treatment of NSCLC with EGFR exon 19 deletions...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Novartis’s ‘Pipeline-In-A-Product’ Assets Progressing Well

 
• By Kevin Grogan

CMO Shreeram Aradhye talks to Scrip about the promise shown by ianalumab, remibrutinib and a next-generation CAR-T for immunological disorders.

Vertex’s Pain Drug Failure Adds To Investor Doubts

 
• By Andrew McConaghie

A Phase II trial to develop a second NaV1.8 pain signal inhibitor for acute pain has failed and the US FDA has given a thumbs down on Journavx’s path to broader use in peripheral neuropathic pain.

Cardiff Pushes Towards Colorectal Cancer Phase III As Funding Questions Loom

 
• By Manas Mishra

Cardiff Oncology is open to going it alone, a partnership and even an exit as the San Diego, CA-based firm tries to push its PLK1 inhibitor through late-stage development.

Aurigene Oncology CEO On Biotech Valuations, CAR-Ts And Reimbursement Models

 
• By Anju Ghangurde

Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.

More from R&D

Allogene Sticks With Standard Lymphodepletion In CAR-T Trial After Patient Death

 
• By Alaric DeArment

The company said it will no longer use ALLO-647 after a patient developed a fatal adenovirus infection, and it will pursue further development of its Dagger technology to minimize or eliminate the need for lymphodepletion.

BioNTech Outlines Development Plan For PD-L1xVEGF-Targeting BNT-327

 
• By Jessica Merrill

The company, with partner Bristol Myers Squibb, has a three-wave development strategy for BNT-327: “establish, combine, broaden.”

AstraZeneca’s Tagrisso Mountain Grows, But The Climb Will Be Challenging

 
• By Aakash Babu

The UK major continues to post promising data readouts that further emphasize the safety and efficacy of its blockbuster lung cancer drug, but competition from J&J's Rybrevant is ramping up, and capable challengers are emerging.